Based on partial restoration of CFTR (CF transmembrane conductance regulator) activity, elexacaftor-tezacaftor-ivacaftor markedly improves pulmonary function and reduces frequency of CF pulmonary exacerbations [1, 2]. Here, CFTR is linked to cystic fibrosis.